Speakers - Sachs Associates

More documents

Recommendations

Info

<strong>Speakers</strong> Eric de La Fortelle, CEO, Delenex Therapeutics Eric is CEO of Delenex Therapeutics AG, a Zurich-based biotechnology company focused on biologic medicines delivered locally for chronic diseases, and administered systemically for acute diseases. The company is currently focused on generating clinical efficacy data in patient studies in three areas: psoriasis, inflammatory bowel disease and acute systemic inflammation. It also uses its proprietary PENTRA® platform to generate a full pipeline of highly stable small antibodies that have comparable affinity and other drug-like properties to existing antibodies, but superior tissue penetration properties and rapid clearance, thus enhancing safety for patients. Formerly, Eric was Global Head, External Research and Technologies, for Roche. During six years there, he headed a worldwide group with a global mandate to find partners, establish contracts and manage alliances with companies offering innovative technologies for every stage of product discovery, development and life cycle. Eric is a scientist by training, with contributions in the field of structure-based drug design (determination of 3D structures of protein targets by X-ray crystallography). He has extensive experience of negotiating Pharma/Biotech alliances (both from the Biotech and the Pharma side). He was trained as an engineer and Physicist at Ecole Centrale de Paris, holds a Ph.D. in Biophysics from Paris XI University, and an MBA from INSEAD. Erik van den Berg, CEO, AM-Pharma B.V. AM-Pharma is a biopharmaceutical company, engaged in the development of novel human alkaline phosphatase therapeutics for unmet needs in severe inflammatory diseases. The Company’s lead programs for this therapeutic enzyme are in Acute Kidney Injury and Inflammatory Bowel Disease. Strong, positive results from Phase II clinical studies using native bovine alkaline phosphatase demonstrated the efficacy of this treatment in patients with Acute Kidney Injury and Moderate-to-Severe Ulcerative Colitis (a type of Inflammatory Bowel Disease), thereby providing proof-of-concept for the development of recombinant human alkaline phosphatase. AM-Pharma’s proprietary human form of this enzyme has been optimized for treating inflammatory conditions and is being produced by cGMP manufacture for preclinical and clinical trial supply and commercialization. AM-Pharma discovered that a key function of alkaline phosphatase is to protect organs against inflammation and tissue damage. While alkaline phosphatase is found in many cells of the human body, it is present at reduced levels in certain diseases including Acute Kidney Injury and Ulcerative Colitis. The Company’s proprietary therapeutics are disease modifying therapies and have the potential to be “first-in-class” medicines. The Company’s business strategy is to advance its human alkaline phosphatase therapeutics through to Phase II development in Acute Kidney Injury, before seeking partners for further clinical development and commercialization. AM-Pharma is currently seeking strategic partners for the further development of its therapeutic in Ulcerative Colitis. Founded in 2001, AM-Pharma is a private company that is based in Bunnik, the Netherlands. The Company is backed by a strong syndicate of international investors and has raised over €55 million equity to date. Esteban Pombo Villar, Chief Operating Officer, Oxford BioTherapeutics AG Esteban is Chief Operations Officer for Oxford Biotherapeutics. Prior to joining OBT, Dr Pombo-Villar was at Novartis for over 20 years, the last 12 years of which he focused on all aspects of creating and managing alliances. Most recently he was Head of Alliance Management at the Novartis Institute for Biomedical Research (NIBR), responsible for alliances up to proof-of-concept in man. He has a PhD in organic chemistry and completed postdoctoral studies at the ETH in Zurich before joining Sandoz Neuroscience Research in Basel in 1988. At Sandoz he worked on drug discovery projects as well as leading collaborative projects investigating the potential of emerging technologies. Dr Pombo-Villar is a Fellow of the Royal Society of Chemistry. Francis Marsland, Head of EU Corporate Development, Biogen Idec Francis is the Site Leader of Biogen Idec’s International HQ in Zug, Switzerland. As VP, European Corporate Development, Francis is responsible for sourcing and transacting European business development and M&A opportunities. Francis advises on Biogen Idec’s European Corporate Strategy, Corporate Communications, Investor Relations, and Government Affairs. Francis was previously Biogen Idec’s Chief International Counsel. t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
<strong>Speakers</strong> Frank Grams, VP, Head Alliance Management & Contracting, Sanofi R&D Frank joined Sanofi in September 2011 as VP, Head R&D Alliance Management & Contracting. In this function he is leading the early stage technology contracting activities and the R&D Alliance Management organization up to POC. Before coming to Sanofi he has been working for Roche as Executive Director, Roche Partnering Asia, and as such has been instrumental in setting up the Roche Pharma Partnering office in Shanghai starting in 2008. The office has been strengthening Roche’s presence in the region from China to Australia. Prior to taking up this post, Frank was Global Head, Drug Delivery Partnering, responsible for both the strategic and lifecycle management activities related to drug delivery partnering. Frank was a Global Alliance Director from 2002, managing pivotal research alliances such as Chugai, Evotec, SGX, Syrrx and Biotie. He has been involved in more than 100 transactions including product and technology deals, in- and out-licensing opportunities and also an acquisition. He is also one of the initiators of the Greater China Life Sciences Business Plan Competition SEED (www.seedcompetition.com). Frank joined the Roche Pharma Partnering team as Head of Opportunity Surveillance in July 2001, having previously worked in various research functions in Roche and at Boehringer Mannheim GmbH. Frank has a degree in chemistry from the University of Heidelberg and received his Ph.D. with summa cum laude from the Technical University of Munich within the group of Nobel laureate Robert Huber (Max-Planck-Institute for Biochemistry at Martinsried, Germany). Frederic Desdouits, EVP, Global Head Business Development – Market Intelligence, Pierre Fabre Frederic is head of Pierre Fabre Group Business Development, Acquisition and Market Intelligence. Prior to join Pierre Fabre, Frederic was a Managing Partner at Bionest Partners, a consulting and transaction firm based in Paris and New York specialized in healthcare and biotechnology; and the founder Managing Partner of Bionest Partners Finance, a boutique specialized in value strategy and fund raising for emerging bio-companies. Before Bionest, Frederic was a partner in charge of Pharmaceutical and Biotechnology sectors at Exane BNP-Paribas, an investment company. Before heading for finance, Frederic work in research for GlaxoWellcome in France (now GSK), as a consultant for Hoechst in the USA and as a PhD student at Rhône-Poulenc in France (now Sanofi). Frederic is graduated from Ecole Polytechnique (Palaiseau), obtained a MS in pharmacology, a PhD in Neurosciences, did a post-doc at the Rockefeller University in New York and is a CEFA (Certified European Financial Analyst). Gerard Plattenburg, CEO, ISA Therapeutics BV Gerard holds a degree as a chemist/molecular biologist from the University of Leiden, The Netherlands. He is currently managing director of ISA Pharmaceuticals B.V. He is responsible for the overall management and strategic direction of ISA Pharmaceuticals. He has more than 20 years senior managerial experience in the biotech industry. Gerard worked for several biotech companies such as Pharming and Genpharm (Medarex) prior to founding Prosensa (a Fierce 15 Biotech company), which he grew into a generally recognized RNA modulation clinical stage company. Graeme Martin, President & CEO, Takeda Research Investment Graeme is President and CEO of Takeda Ventures, Inc (TVI), the corporate venture arm of Takeda Pharmaceutical Company, Ltd. Since joining Takeda in 2003, Dr Martin has overseen investment of $49mm into 18 early and mid-stage biotechnology companies, the result of which has been several strategic relationships with Takeda R&D operations. During more than 30 years R&D management in multinational Pharmaceutical and Biotech companies in Europe and the USA, Dr Martin has pursued scientific enquiry with a passion, resulting in IND submissions for three novel drug candidates one of which, under the brand name Zomig®, is marketed worldwide for the acute treatment of migraine. He is the author of more than 85 peerreviewed publications and book chapters, obtaining his Bachelor of Science degree in Pharmacology from the University of Bath, UK and his doctorate from University College, London, UK. t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
Page 1 and 2: B I O T E C H I N E U R O P E I N V
Page 3 and 4: Events Diary For regular updates, s
Page 5 and 6: Speakers Alexey Eliseev, Managing D
Page 7 and 8: Speakers Blake M. Paterson, Co-Foun
Page 9: Speakers David Slack, Head of Corpo
Page 13 and 14: Speakers Iain Buchanan, CEO, NOXXON
Page 15 and 16: Speakers Juhani Lahdenperä, CEO, H
Page 17 and 18: Speakers Marcel Zwaal, CBO, DCPrime
Page 19 and 20: Speakers Paul Higham, Managing Dire
Page 21 and 22: Speakers Richard Goodfellow, CEO, S
Page 23 and 24: Speakers Søren Moller, Managing In
Page 25 and 26: CONTACT Robert F Burns, PhD Chief E
Page 27 and 28: CONTACTS Rostislav Raykov Chief Exe
Page 29 and 30: CONTACTS Vincent Charlon PhD, CEO Z
Page 31 and 32: CONTACTS Dr Bassam Damaj Chairman,
Page 33 and 34: CONTACT Carina Schmidt Chief Execut
Page 35 and 36: CONTACT Mr Richard Godfrey Chief Ex
Page 37 and 38: CONTACTS Tom Kronbach, PhD Chief Ex
Page 39 and 40: CONTACTS Andreas Caduff, PhD Chief
Page 41 and 42: CONTACTS Dr Blake Paterson Co-Found
Page 43 and 44: CONTACT Wolfgang Kintzel Chief Exec
Page 45 and 46: CONTACT Mike Romanos PhD Chief Exec
Page 47 and 48: CONTACT Harry Welten, MBA Chief Fin
Page 49 and 50: CONTACT Barbara Stiefel Office Mana
Page 51 and 52: CONTACTS Ana Martinez Assistant Jua
Page 53 and 54: CONTACTS Dr Rudi D Neirinckx Chief
Page 55 and 56: CONTACT Martin Bonde, PhD, BComm Ch
Page 57 and 58: CONTACT Benedikt Timmerman Chief Ex
Page 59 and 60: CONTACT Malcolm Weir Chief Executiv
Page 61 and 62:
CONTACTS Mr Paul Higham Chief Execu
Page 63 and 64:
CONTACTS Kevin FitzGerald Chief Ope
Page 65 and 66:
CONTACT Roel Q. J Schaapveld, PhD,
Page 67 and 68:
CONTACT Maaike Vogelezang Managemen
Page 69 and 70:
CONTACT Tom Johnston Chief Executiv
Page 71 and 72:
CONTACTS Aaron Powers President Dav
Page 73 and 74:
CONTACTS General and Media Contact
Page 75 and 76:
CONTACTS Martin Welschof Chief Exec
Page 77 and 78:
CONTACTS Carlos Buesa Chief Executi
Page 79 and 80:
CONTACTS Nick McCooke Chief Executi
Page 81 and 82:
CONTACT Dr Erik Buntinx Chief Execu
Page 83 and 84:
CONTACT Michael Altorfer, Ph.D. Hea
Page 85 and 86:
CONTACT Matthew B. Lehman Chief Ope
Page 87 and 88:
ADDRESS Otto-Hahn-Strasse 15 D- 442
Page 89 and 90:
CONTACT Dr Roman Schenk Chief Execu
Page 91 and 92:
CONTACTS Dr Hans Fliri Chairman Sim
Page 93 and 94:
CONTACTS Dr Raúl Insa Chief Execut
Page 95 and 96:
CONTACT Dr Johanna Holldack, MD Chi
Page 97 and 98:
CONTACT Eduardo Bravo (speaker) Man
Page 99 and 100:
CONTACTS Piers Morgan Chief Financi
Page 101 and 102:
CONTACT Jakob Knudsen Chief Executi
Page 103 and 104:
CONTACTS Dr Sonja Reingruber Chief
Page 105 and 106:
Supporting Organisations Citigate D
Page 107 and 108:
Supporting Organisations Life Scien
Page 109 and 110:
Supporting Organisations Swiss Biot
Page 111 and 112:
Supporting Organisations Torreya Pa
Page 113:
B I O T E C H I N E U R O P E I N V
show all

Speakers - Sachs Associates

Create successful ePaper yourself

Delete template?

Save as template?